Egypt: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Egypt

In 2022, the Egyptian prophylactic medicaments containing insulin market increased by 42% to $X, rising for the second year in a row after four years of decline. Over the period under review, consumption, however, saw a drastic downturn. Prophylactic medicaments containing insulin consumption peaked at $X in 2016; however, from 2017 to 2022, consumption failed to regain momentum.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from Egypt

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses decreased by -63% to X tons for the first time since 2018, thus ending a three-year rising trend. Over the period under review, exports, however, posted a significant increase. The most prominent rate of growth was recorded in 2013 with an increase of 2,960%. As a result, the exports reached the peak of X tons. From 2014 to 2022, the growth of the exports remained at a lower figure.

In value terms, prophylactic medicaments containing insulin exports fell notably to $X in 2022. In general, exports, however, continue to indicate a significant expansion. The pace of growth was the most pronounced in 2013 when exports increased by 2,714%. The exports peaked at $X in 2021, and then reduced notably in the following year.

Exports by Country

Kenya (X tons) was the main destination for prophylactic medicaments containing insulin exports from Egypt, accounting for a 97% share of total exports. It was followed by Rwanda (X kg), with a 3.2% share of total exports.

From 2012 to 2022, the average annual growth rate of volume to Kenya totaled +115.9%.

In value terms, Kenya ($X) emerged as the key foreign market for medicaments containing insulin but not antibiotics in measured doses exports from Egypt, comprising 97% of total exports. The second position in the ranking was taken by Rwanda ($X), with a 3.2% share of total exports.

From 2012 to 2022, the average annual growth rate of value to Kenya stood at +168.6%.

Export Prices by Country

The average prophylactic medicaments containing insulin export price stood at $X per ton in 2022, surging by 125% against the previous year. Overall, the export price recorded significant growth. As a result, the export price reached the peak level and is likely to continue growth in the immediate term.

Average prices varied noticeably for the major overseas markets. In 2022, amid the top suppliers, the country with the highest price was Rwanda ($X per ton), while the average price for exports to Kenya amounted to $X per ton.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to India (+124.5%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into Egypt

In 2022, overseas purchases of medicaments containing insulin but not antibiotics in measured doses increased by 42% to X tons, rising for the second year in a row after two years of decline. Over the period under review, imports, however, showed a deep downturn. The pace of growth was the most pronounced in 2021 when imports increased by 119%. Over the period under review, imports hit record highs at X tons in 2016; however, from 2017 to 2022, imports stood at a somewhat lower figure.

In value terms, prophylactic medicaments containing insulin imports expanded markedly to $X in 2022. Overall, imports, however, showed a pronounced reduction. The pace of growth appeared the most rapid in 2021 when imports increased by 128%. Over the period under review, imports attained the maximum at $X in 2016; however, from 2017 to 2022, imports failed to regain momentum.

Imports by Country

In 2022, Germany (X tons) was the main supplier of prophylactic medicaments containing insulin to Egypt, accounting for a 93% share of total imports. Moreover, prophylactic medicaments containing insulin imports from Germany exceeded the figures recorded by the second-largest supplier, Denmark (X tons), more than tenfold. The third position in this ranking was taken by India (X kg), with a 1.9% share.

From 2012 to 2022, the average annual growth rate of volume from Germany stood at -3.9%. The remaining supplying countries recorded the following average annual rates of imports growth: Denmark (+45.0% per year) and India (+36.1% per year).

In value terms, Germany ($X) constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to Egypt, comprising 95% of total imports. The second position in the ranking was taken by Denmark ($X), with a 3.5% share of total imports. It was followed by France, with a 1.4% share.

From 2012 to 2022, the average annual rate of growth in terms of value from Germany was relatively modest. The remaining supplying countries recorded the following average annual rates of imports growth: Denmark (+83.2% per year) and France (-16.9% per year).

Import Prices by Country

The average prophylactic medicaments containing insulin import price stood at $X per ton in 2022, which is down by -21.4% against the previous year. Over the period under review, the import price, however, enjoyed a moderate increase. The pace of growth was the most pronounced in 2014 when the average import price increased by 81% against the previous year. Over the period under review, average import prices reached the peak figure at $X per ton in 2021, and then fell remarkably in the following year.

There were significant differences in the average prices amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was Denmark ($X per ton), while the price for India ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Denmark (+26.4%), while the prices for the other major suppliers experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :